Treace Medical Concepts Updates FY23 Revenue From $191M-$197M To $182M-$186M Vs $194.32M Est.
Portfolio Pulse from Benzinga Newsdesk
Treace Medical Concepts has revised its FY23 revenue guidance from $191M-$197M to $182M-$186M, representing a 28%-31% growth over the company's 2022 revenue. The company expects positive adjusted EBITDA in Q4 2023 and a modest improvement in adjusted EBITDA for the full year 2023 compared to 2022.
November 09, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Treace Medical Concepts has lowered its FY23 revenue guidance, which may negatively impact investor sentiment and potentially the stock price in the short term.
Companies often see their stock prices affected by changes in earnings guidance. In this case, Treace Medical Concepts has lowered its revenue guidance for FY23, which could lead to negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100